Eiger BioPharmaceuticals Class Action Deadline: Submit Your Losses to Johnson Fistel
The Class Action Seeks to Recover Damages on EIGR Shareholders’ Behalf SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) — Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on more...
Kona Gold Beverage, Inc Signs Distribution Agreements with Dahlheimer Beverage and Michaud Distributing in Minnesota
Melbourne, FL, Jan. 04, 2023 (GLOBE NEWSWIRE) — Kona Gold Beverage, Inc. (OTC: KGKG), a holding company focused on product development in the better-for-you and functional beverage sector is pleased to announce it has signed more...
Rocky Mountain High Brands Goes Back To Its Roots
PLANO, Texas, Jan. 04, 2023 (GLOBE NEWSWIRE) — Rocky Mountain High Brands, Inc. (OTC: RMHB) today announced the return of Rocky Mountain High hemp-infused energy drinks in three bold flavors: Mango, Citrus, and Black Tea. more...
Silicom 5G-Native Edge Networking Product Selected By SD-WAN Leader
Silicom 5G-Native Edge Networking Product Selected By SD-WAN Leader PR Newswire KFAR SAVA, Israel , Jan. 4, 2023 /PRNewswire/ — Silicom Ltd. (NASDAQ: SILC), a leading provider of networking and data infrastructure solutions, today announced that more...
Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
Positive and clinically meaningful pivotal clinical results announced in 2022 in both metastatic and locally advanced indications WALTHAM, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and more...
SOL Global Divests Securities in Captor Capital
Toronto, Ontario–(Newsfile Corp. – January 4, 2023) – SOL Global Investments Corp. (CSE: SOL) (OTC Pink: SOLCF) (FSE: 9SB) (“SOL Global” or the “Company”) announces that the Company transferred and divested an aggregate of 4,182,316 common shares (“Captor more...
Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer
SYDNEY, AUSTRALIA, Jan. 04, 2023 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that it more...
Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from its Cloudbreak® Platform
CBO-212 is a first-in-class inhibitor of CD73 cancer immunotherapy target SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of more...
Akari Therapeutics to Present at Biotech Showcase(TM) 2023
NEW YORK and LONDON, Jan. 04, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Akari President and CEO Rachelle more...
Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol
Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol PR Newswire Histological improvement in fibrosis (≥1 stage) was demonstrated in 39% of subjects according more...